Selbstmedikation bei Migräne und beim Kopfschmerz vom Spannungstyp

G. Haag; H.-C. Diener; A. May; C. Meyer; H. Morck; A. Straube; P. Wessely; S. Evers

doi:10.1055/s-0038-1628650

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2009; 28(06): 382-397
DOI: 10.1055/s-0038-1628650

Leitlinie

Schattauer GmbH

Selbstmedikation bei Migräne und beim Kopfschmerz vom Spannungstyp

Evidenzbasierte Empfehlungen der Deutschen Migräneund Kopfschmerzgesellschaft (DMKG), der Deutschen Gesellschaft für Neurologie (DGN), der Österreichischen Kopfschmerzgesellschaft (ÖKSG) und der Schweizerischen Kopfwehgesellschaft (SKG)Self medication in migraine and tension type headacheGuidelines of the German, Austrian and Swiss headache societies and the German

G. Haag

¹Michael-Balint-Klinik, Königsfeld

,

H.-C. Diener

²Klinik und Poliklinik für Neurologie, Universitätsklinikum Essen

,

A. May

³Institut für Systemische Neurowissenschaften, Universitätsklinikum Hamburg-Eppendorf

,

C. Meyer

⁴Neurologische Praxis, Baden/Schweiz

,

H. Morck

⁵Pharmazeutische Zeitung, Eschborn

,

A. Straube

⁶Neurologische Klinik der Universität München, Klinikum Großhadern

,

P. Wessely

⁷Neurologische Praxis, Wien

,

S. Evers

⁸Klinik und Poliklinik für Neurologie, Universitätsklinikum Münster

› Institutsangaben

Abstract

Zusammenfassung

Die evidenzbasierte Leitlinie (S3-Leitlinie)über die Selbstmedikation bei Migräne und Spannungskopfschmerz der deutschen, österreichischen und schweizerischen Kopfschmerzgesellschaften und der DeutschenGesellschaft für Neurologie (DGN) richtet sich an in der Primärversorgung tätige Ärzte, anApotheker und Patienten. Trotz der gesundheitsökonomischen Bedeutung der Selbstmedikationfanden sich im internationalen Schrifttum keine vergleichbaren Leitlinien. Zuden bewerteten nicht rezeptpflichtigen Substanzenenthalten die Literaturbanken Medlineund Cochran 59 Studien, die in die Bewer-tung eingeschlossen werden konnten. DieWirksamkeit der Selbstmedikation bei einerMigräneattacke ist für folgende Substanzenoder Substanzkombinationen wissenschaftlichbelegt: Fixe Kombination aus Acetylsalicylsäure,Paracetamol und Koffe in sowie die Monotherapiemit Acetylsalicylsäure oder Ibuprofen oder Naratriptan oder Paracetamol oder Phenazon.Zur Selbstmedikation im Rahmen derMigräneprophylaxe kann die Wirksamkeit beikeiner der rezeptfrei erhältlichen Substanzenals wissenschaftlich eindeutig belegt eingestuftwerden. Zur Selbstmedikation bei Kopfschmerzenvom Spannungstyp können folgendefixe Kombinationen oder Monosubstanzenempfohlen werden: Fixe Kombination aus Acetylsalicylsäure,Paracetamol und Koffein bzw. aus Paracetamol und Koffe in sowie die Monother apienmit Ibuprofen oder Acetylsalicylsäureoder Diclofenac.

Summary

The actual evidence based guideline about self medication in migraine and tension type headache of the German, Austrian and Swiss headache societies and the German Society of Neurology is addressed to physicians engaged in the primary care as well as pharmacists and also patients. The guideline takes especially concern about the description of the used methodology of the selection process of the used literature and on which evidence there commendations are based. The following recommendations about self medication inmigraine attacks can be made: The effectiveness of the fixed combination of acetaminophen, acetylsalicylate and caffe in and the monotherapy with ibuprofen or naratriptaneor acetaminophen or phenacon are scientificallyproven; none of the substance used in the self medication in migraine prophylaxiscan be seen as proven effective. Concerningthe self medication in tension type headache the following option can be recommended:the fixed combination of acetaminophen, acetylsalicylic acid and caffein as well as thefixed combination of acetaminophen and caffeinas well as the monotherapy with ibuprofenor acetylsalicylic acid or diclofenac.

Schlüsselwörter

Migräne - Kopfschmerz vom Spannungstyp,Selbstmedikation - evidenzbasierte Behandlungsempfehlungen

Keywords

Migraine - tension-type headache - self medication,evidence based treatment recommendations.

Volltext

Referenzen

Literatur
1 Akobeng AK. Principles of evidence based medicine. Arch Dis Child 2005; 90: 837-840.
2 Allison JJ, Saag E, Saag KG. Unbalanced regulation of over-the-counter analgesics: the lesser of two evils?. Pharmacoepidemiology Drug Safety 2006; 15: 410-411.
3 Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T. for the CONSORT group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2002; 134: 663-694.
4 Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998; 51: 1357-1365.
5 Bellomo R, Bagshaw SM. Evidence-based medicine: Classifying the evidence from clinical trials – the need to consider other dimensions. Critical Care 2006; 10: 232.
6 Berger VW, Christophi CA. Randomization technique, allocation concealment, masking, and susceptibility of trials to selection bias. J Mod Appl Stat Methods 2003; 02: 80-86.
7 Berger VW, Weinstein S. Ensuring the comparability of comparison groups: is randomization enough?. Control Clin Trials 2004; 25: 515-524.
8 Bergmann JF. Self-medication: from European regulatory directives to therapeutic strategy. Fundam Clin Pharmacol 2003; 17: 275-280.
9 Berman NG, Parker RA. Meta-analysis: Neither quick nor easy. BMC Medical Research Methodology 2002; 02: 10.
10 Bickley SR, Harrison JE. How to … find the evidence. J Orthodontics 2003; 30: 72-78.
11 Bigal ME, Bordini CA, Speciali JG. Efficacy of three drugs in the treatment of migrainous aura: a randomized placebo-controlled study. Arqu Neuropsiquiatr 2002; 60 (2-B): 406-409.
12 Bomhof M, Paz J, Legg N, Allen C. Vandormael K. Patel K. Comparison of rizatriptan 10 mg vs.naratriptan 2.5 mg in migraine. Eur Neurol 1999; 42: 173-179.
13 Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl K M, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004; 11: 475-477.
14 Brunton L, Parker K, Blumenthal D, Buxton I. Goodman & Gilman’s Manual of pharmacology and therapeutics. New York: McGraw Hill; 2007
15 Chan AW, Hrobjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials – comparison of protocols to published articles. JAMA 2004; 291: 2457-2465.
16 Chou R. Using Evidence in Pain Practice. Pain Med 2008; 09: 518-541.
17 Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache 2003; 43: 76-78.
18 DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJPM, Schroeder TV, Sox HC, Van der Weyden MB. Clinical trial registration – a statement from the International Committee of Medical Journal Editors. JAMA 2004; 292: 1363-1364.
19 Deeks JJ, Altman DG. Inadequate reporting of controlled trials as short reports. Lancet 1998; 352: 1908.
20 Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635-641.
21 Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004; 51: 89-97.
22 Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Göbel H, Hartung E, Jimenez MD, Lange R, Manzoni GC, MuellerSchwefe G, Nappi G, Pinessi L, Prat J, Puca FM, Titus F, Voelker M. EMSASI Study Group. Placebocontrolled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24: 947-954.
23 Diener HC, Eikermann A, Gessner U, Göbel H, Haag G, Lange R, May A, Müller-Schwefe G, Voelker M. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004; 52: 50-56.
24 Diener HC. Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005; 25: 776-787.
25 Diener HC, Lampl C, Reimitz P, Voelker M. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurotherap 2006; 06: 563-573.
26 Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B, Lipton RB. Headache classification by history has only limited predictive value for headache episodes treated in controlled trials with OTC analgesics. Cephalalgia 2009; 29: 188-193.
27 Driscoll P, Lecky F, Crosby M. An introduction to everyday statistics. Part 1. J Accid Emerg Med 2000; 17: 205-211.
28 European Agency for the Evaluation of Medicinal Products (EMEA). ICH Topic E 9 Statistical Principles for Clinical Trials. Step 5. Note for guidance on statistical principles for clinical trials. CPMP/ ICH/363/96 – September 1998
29 European Agency for the Evaluation of Medicinal Products (EMEA): Points to consider on switching between superiority and non-inferiority. London. CPMP/EWP/482/99 – July 2000
30 European Medicines Agency (EMEA): Guideline on the choice of the non-inferiority margin. London, EMEA/CPMP/EWP/2158/99 – July. 2005
31 Evans M, Pollock A. A score system for evaluating random control clinical trials of prophylaxis of abdominal surgical wound infection. Br J Surg 1985; 72: 256-260.
32 Evans T, Gülmezoglu M, Pang T. Registering clinical trials: an essential role for WHO. Lancet 2004; 363: 1413-1414.
33 Evers S, May A, Fritsche G, Kropp P, Lampl C, Limmroth V, Malzacher V, Sandor P, Straube A, Diener HC. Akuttherapie und Prophylaxe der Migräne – Leitlinie der Deutschen Migräneund Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. Nervenheilkunde 2008; 27: 933-949.
34 Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache 1991; 31: 298-301.
35 Farinelli I, Martelletti P. Aspirin and tension-type headache. J Headache Pain 2007; 08: 49-55.
36 Feleppa M, Apice G, D’Alessio A, Fucci S, Bigal ME. Tolerability of acute migraine medications: influence of methods of assessment and relationship with headache attributes. Cephalalgia 2008; 28: 1012-1016.
37 Formann AK. Estimating the proportion of studies missing for meta-analysis due to publication bias. Contemp Clin Trials 2008; 29: 732-739.
38 García-Berthou E, Alcaraz C. Incongruence between test statistics and P values in medical papers. BMC Med Res Methodol 2004; 04: 13.
39 Garcia-Ramos G. MacGregor EA. Hilliard B. Bordini CA. Leston J. Hettiarachchi J. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003; 23: 869-876.
40 Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J 1986; 292: 746-750.
41 Garg AX, Greene T, Levin NW. A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrol Dial Transplant 2008; 23: 52-55.
42 Gehr BT, Weiss C, Porzsolt F. The fading of reported effectiveness. A meta-analysis of randomised controlled trials. BMC Med Res Methodol 2006; 06: 25.
43 Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 2007; 47: 1074-1086.
44 Göbel H, Heinze A, Dworschak M, Heinze-Kuhn K, Stolze H. Oleum menthae piperitae in der Akuttherapie von Migräne und Kopfschmerz vom Spannungstyp. Z Phytother 2004; 25: 129-139.
45 Göbel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebocontrolled, randomized study. Cephalalgia 2004; 24: 888-893.
46 Goldstein J. Silberstein SD. Saper JR. Elkind AH. Smith TR. Gallagher RM. Battikha JP. Hoffman H. Baggish J. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache 2005; 45: 973-982.
47 Goldstein J, Silberstein SD, Saper JR, Ryan RE, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006; 46: 444-453.
48 Gracely E. So, why do I have to correct for multiple comparisons? Concepts and commentary on Turk et al. Pain 2008; 139: 481-482.
49 Grigorova NA, Leshchenko OK. Current aspects of the treatment of migraine. Likarska Sprava 2003; 5–6: 80-85.
50 Grimshaw J, Eccles M, Russell I. Developing clinically valid practice guidelines. J Eval Clin Pract 1995; 01: 37-48.
51 Grossman M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38: 430-435.
52 Haag G, Evers S, May A, Neu IS, Vivell W, Ziegler A. Selbstmedikation bei Migräne und Kopfschmerz vom Spannungstyp. Evidenzbasierte Empfehlungen der Deutschen Migräneund Kopfschmerzgesellschaft (DMKG). Nervenheilkunde 2004; 23: 415-430.
53 Haas DC, Sheehe PR. Dextroamphetamine pilot crossover trials and n of 1 trials in patients with chronic tension-type and migraine headache. Headache 2004; 44: 1029-1037.
54 Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002; 288: 358-362.
55 Hamunen K, Kalso E. A systematic review of trial methodology, using the placebo groups of randomized controlled trials in paediatric postoperative pain. Pain 2005; 116: 146-158.
56 Hardman JG, Limbird LE. Goodman & Gilman’s The pharmacological basis of therapeutics. 9th edition. New York: McGraw Hill; 1995
57 Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H. Efficacy of naratriptan tablets in the acute treatment of migraine: a doseranging study. Naratriptan S2WB2004 Study Group. Clin Therap 2000; 22: 970-980.
58 Headache Classification Subcommittee of International Headache Society. (ICHD-II) International classification of headache disorders. Cephalalgia 2004; 24 (Suppl. 01) 14-160.
59 Helou A, Lorenz W, Ollenschlager G, Reinauer H, Schwartz FW. Methodische Standards der Entwicklung evidenzbasierter Leitlinien in Deutschland. Konsens zwischen Wissenschaft, Selbstverwaltung und Praxis. Z Ärztl Fortbild Qualitätssich 2000; 94: 330-339.
60 Helou A, Perleth M, Schwartz FW. Prioritätensetzung bei der Entwicklung medizinischer Leitlinien. Teil 1: Kriterien, Verfahren und Akteure: eine methodische Bestandsaufnahme internationaler Erfahrungen. Z Ärztl Fortbild Qualitätssich 2000; 94: 53-60.
61 Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, Segers A, Burdine D, Manning P, Kabbouche MA. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007; 47: 73-80.
62 Hofmann R. More to be said on “Triptans vs other drugs for acute migraine. Are there differences in efficacy?”. Headache 2008; 49: 312-313.
63 Ioannidis JPA. Effect of the statistical significance of results on time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281-286.
64 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12.
65 Jackson D. The implications of publication bias for meta-analysis’other parameter. Statist Med 2006; 25: 2911-2921.
66 Juhl RP. Prescription to over-the-counter switch: A regulatory perspective. Clin Therap 1998; 20 Suppl C: C111-C117.
67 Kendall JM. Designing a research project: randomised controlled trials and their principles. Emerg Med J 2003; 20: 164-168.
68 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-989.
69 Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache 1997; 37: 640-645.
70 Kopp IB, Selbmann HK, Koller M. Konsensfindung in evidenzbasierten Leitlinien – vom Mythos zur rationalen Strategie. Z Ärztl Fortbild Qualitätssich 2007; 101: 89-95.
71 Kubitzek F, Ziegler G, Gold ML, Liu JMH, Ionescu E. Low-dose diclofenac potassium in the treatment of episodic tension-type headache. Eur J Pain 2003; 07: 155-162.
72 Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S, Northam RS, White LW, Lawson L. Children’s ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002; 42: 780-786.
73 Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63: 2240-2244.
74 Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. Headache 2005; 45: 283-292.
75 Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 2008; 08: 22.
76 Ma J, Liu W, Hunter A, Zhang W. Performing metaanalysis with incomplete statistical information in clinical trials. BMC Med Res Methodol 2008; 08: 56.
77 Macedo A, Farré M, Baños JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol 2006; 62: 161-172.
78 MacGregor EA. Dowson A. Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 2002; 42: 249-255.
79 Magis D, Ambrosini A, Sandor P, Jacquy J, Laloux P, Schoenen J. A randomized double-blind placebocontrolled trial of thioctic acid in migraine prophylaxis. Headache 2007; 47: 52-57.
80 Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44: 885-890.
81 Martelletti P, Farinelli I, Coloprisco G, Patacchioli FR. Role of NSAIDs in acute treatment of headache. Drug Dev Res 2007; 68: 276-281.
82 Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C. The French Naramig Collaborative Study Group. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol 2005; 12: 774-781.
83 Matchar DB, Young WB, Rosenberg JH, Pietrzak MP, Silberstein SD, Lipton RB, Ramadan NM. Evidence-based guidelines for migraine headache in primary care settings: pharmacological management of acute attacks. 2000 www.aan.com/profes sionals/practice/guidelines.cfm.
84 Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 1997; 49: 1485-1490.
85 McDonald S, Antes G, Galandi D, Gøtzsche P, Hammarquist C, Haugh M, Jensen KL, Kleijnen J, Loep M, Pistotti V, Rüther A. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. Eval Health Prof 2002; 25: 65-75.
86 McQuay H, Moore A. An evidence-based resource for pain relief. Oxford: University Press; 1998
87 Migliardi JR, Armellino JJ, Friedman M, Gillings DB, Beaver WT. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56: 576-586.
88 Misra UK. Jose M. Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J 2004; 80: 720-723.
89 Moher D, Schulz KF. Altman DG·(für die CONSORT Gruppe). Das CONSORT Statement Überarbeitete Empfehlungen zur Qualitätsverbesserung von Reports randomisierter Studien im ParallelDesign. Schmerz 2005; 19: 156-162.
90 Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 1994; 272: 122-124.
91 Moore N, Van Ganse E, Le Parc JM, Wall R, Schneid H, Farhan M, Verirere F, Pelen F. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. Clin Drug Invest 1999; 18: 89-98.
92 Nieber K. Mehr Glaubwürdigkeit bei AWBs. Pharm Ztg 2007; 152: 2950.
93 Packman B, Packman E, Doyle G, Cooper S, Ashraf E, Koronkiewicz K, Jayawardena S. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache. Headache 2000; 40: 561-567.
94 Pageler L, Diener HC, Pfaffenrath V, Peil H, Aicher B. Clinical relevance of efficacy endpoints in OTC trials. Headache. 2009 (doi: 10.1111/ j.1526–4610.2008.0124).
95 Parfitt K. Analgesics, anti-inflammatory drugs and antipyretics – aspirin. In: Parfitt K. (ed). Martindale – The complete drug reference. 32th edition.. London: Pharmaceutical Press; 1999
96 Peikert A, Willimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-263.
97 Peres MFP, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004; 63: 757.
98 Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005; 25: 403-411.
99 Peres MF, Masruha MR, Zukerman E, MoreiraFilho CA, Cavalheiro EA. Potential therapeutic use of melatonin in migraine and other headache disorders. Exp Op Investig Drugs 2006; 15: 367-375.
100 Pfaffenrath V, Wessely P, Meyer C, Isler H, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M. Magnesium in the prophylaxis of migraine. A double-blind, placebo-controlled study. Cephalalgia 1996; 16: 436-440.
101 Philipp M. Therapy of migraine. Clinical experience with Migraeflux, a new migraine drug. Fortschr Med 1977; 95: 107-110.
102 Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials – an extension of the CONSORT statement. JAMA 2006; 295: 1152-1160.
103 Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 2005; 45: 196-203.
104 Pradalier A, Bakouche P, Baudesson G, Delage A, Cornaille-Lafage G, Launay JM, Biason P. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia 2001; 21: 818-822.
105 Pray WS. Nonprescription medications and self care. Ethical, scientific, and educational concerns with unproven medications. Am J Pharm Educ 2006; 70: 141.
106 Reeves BC. Principles of research: limitations of non-randomized studies. Surgery 2003; 21: 129-33.
107 Rosmarakis ES, Soteriades ES, Vergidis PI, Kasiakou SK, Falagas ME. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J 2005; 19: 673-680.
108 Royle P, Waugh N. A simplified search strategy for identifying randomised controlled trials for systematic reviews of health care interventions: a comparison with more exhaustive strategies. BMC Med Res Methodol 2005; 05: 23.
109 Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 137-141.
110 Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine – how to practice and teach EBM. Edinburgh: Churchill Livingstone; 2000
111 Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64: 713-715.
112 Saper J, Dahlöf C, So Y, Tfelt-Hansen P, Malbecq W, Loeys T, Barraclough E, Klipfel M, Lines C, Visser H, Reines S, Yuen E. Rofecoxib Protocol 162 Study Group. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache 2006; 46: 264-275.
113 Sauerland S, Neugebauer E. Qualität von MetaAnalysen. In: Lauterbach KW, Schrappe M. (Hrsg). Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine. Stuttgart: Schattauer; 2001: 89-95.
114 Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14: 328-329.
115 Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-470.
116 Schulz KF, Grimes DA. Blinding in randomized trials: hiding who got what. Lancet 2002; 359: 696-700.
117 Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005; 365: 1591-1595.
118 Shekelle PG, Morton SC, Suttorp MJ, Buscemi N, Friesen C. Challenges in systematic reviews of complementary and alternative medicine topics. Ann Intern Med 2005; 142: 1042-1047.
119 Silberstein SD, Rosenberg J. Multispeciality consensus on diagnosis and treatment of headache. Neurology 2000; 54: 1553.
120 Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O’Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40: 513-520.
121 Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000 mg). Cephalalgia 1998; 18: 38-43.
122 Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled doseranging comparison with paracetamol. Cephalalgia 2003; 23: 59-66.
123 Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007; 41: 1782-1791.
124 Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for Migraine – What are the implications?. CNS Drugs 2007; 21: 877-883.
125 Tfelt-Hansen P, Bjarnason NH, Dahlöf C, Derry S, Loder E, Massiou H. for the Task Force on Adverse Events in Migraine Trials of the Subcommittee on Clinical Trial of the International Headache Society. Evaluation and registration of adverse events in clinical drug trials in migraine. Cephalalgia 2008; 28: 683-688.
126 Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol 2008; 08: 45.
127 Turk DC, Dworkin RH, McDermott MP. et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Pain 2008; 139: 485-493.
128 Walach H, Häusler W, Lowes T, Mussbach D, Schamell U, Springer W, Stritzl G, Gaus W, Haag G. Classical homeopathic treatment of chronic headaches. Cephalalgia 1997; 17: 119-126.
129 Waldvogel HH. Analgetika, Antinozizeptiva, Adjuvanzien. Handbuch für die Schmerzpraxis. 2. Auflage. Berlin: Springer; 2001
130 Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 2003; 43: 601-610.
131 West RR. Evidence based medicine overviews, bulletins, guidelines, and the new consensus. Postgrad Med J 2000; 76: 383-389.
132 Whitmarsch TE, Coleston-Shields DM, Steiner TH. Double-blind randomised placebo-controlled study of homeopathic prophylaxis of migraine. Cephalalgia 1997; 17: 600-604.
133 Zukerman E, Negro MHS, Nothen MR. Comparative study on the efficacy and tolerability of different formulations for Tonopan versus placebo in migraine. Rev Bras Neurol 1990; 26: 57-60.
134 Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: 1223-1226.